Why Alpha Tau Medical Ltd.’s (DRTS) Stock Is Up 5.64%
As of Friday, July 17, Alpha Tau Medical Ltd.’s DRTS share price has surged by 5.64%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Alpha Tau Medical Ltd. (DRTS)
Alpha Tau Medical Ltd. DRTS
$14.81
0.30
2.07%
October 2, 2026 11:59:40 AM
EST
Volume: 89,438
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Commentary & Analysis
Why Alpha Tau Medical Ltd.’s (DRTS) Stock Is Up 13.26%
As of Friday, July 17, Alpha Tau Medical Ltd.’s DRTS share price has surged by 13.26%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Alpha Tau Medical Ltd.’s (DRTS) Stock Is Down 6.16%
As of Friday, July 10, Alpha Tau Medical Ltd.’s DRTS share price has dipped by 6.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Alpha Tau Medical Ltd.’s (DRTS) Stock Is Down 8.36%
As of Tuesday, July 07, Alpha Tau Medical Ltd.’s DRTS share price has dipped by 8.36%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Alpha Tau Medical Ltd.’s (DRTS) Stock Is Up 5.08%
As of Tuesday, June 30, Alpha Tau Medical Ltd.’s DRTS share price has surged by 5.08%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | DRTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,339.7 | $378.7 | 49% |
|
| Shares Out (Mil) | 91.0 | 41.2 | 60% |
|
| Institutional Ownership | 37.6% | 82.9% | 16% |
|
| Float (Mil) | 64.1 | 35.5 | 52% |
|
| Beta | 1.18 | 0.86 | 70% |
|
| Avg Daily Volume (000s) | 469 | 351 | 54% |
|
| Price Change (52-week) |
221.7% | 64.6% | 98% |
|
| Growth | DRTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (36.8%) | (5.7%) | 11% |
|
| EPS (5yr) | (19.1%) | 10.2% | 14 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.5%) | (15.5%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | ($0.147) | ($0.955) | ($0.535) | |
| Month Ago EPS | ($0.142) | ($0.878) | ($0.527) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 3 | |
| Three Months Ago EPS | ($0.138) | ($0.659) | ($0.515) | |
| Year/Year Chg | (70.8%) | 80.5% | (33.8%) | |
| Financials | DRTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $128 | na |
|
| Net Income (TTM) (Mil) | ($93) | ($9) | 12% |
|
| EPS (TTM) | ($1.052) | ($0.400) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($3) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $14 | $25 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,231 | $399 | 43% |
|
| Valuation | DRTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 30.23 | 2.74 | 97% |
|
| P/E | na | 24.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | DRTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 59.0% | na |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (80.4%) | (12.3%) | 7% |
|
| ROE | (156.8%) | (10.8%) | 6% |
|
| Liabilities to Assets | 67.2% | 47.1% | 63% |
|
| F-Score | 1 | 4 | 1% |
|
Passing Stock Screens
As of 10/1/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 3.0% |
| +/- S&P 500: | -4.5 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.3% |
| +/- S&P 500: | -5.2 |
